Wilko Flea Drops 268 mg Spot-on Solution for Large Dogs

Summary of Product characteristics

                                Revised: May 2018
AN: 01756/2017
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Wilko Flea Drops 268 mg Spot-on Solution for Large Dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One 2.68 ml pipette contains:
ACTIVE SUBSTANCE:
Fipronil
268 mg
EXCIPIENTS:
Butylhydroxyanisole E320
0.536 mg
Butylhydroxytoluene E321
0.268 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Spot-on solution.
Clear, pale amber solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE,SPECIFYING THE TARGET SPECIES
Treatment of flea (Ctenocephalides spp.) and tick (Rhipicephalus
sanguineus and
Ixodes ricinus) infestations.
Insecticidal efficacy against new infestations with adult fleas
persists for 8 weeks.
The product has a persistent acaricidal efficacy for 4 weeks against
ticks
(Rhipicephalus sanguineus, Ixodes ricinus, Dermacentor reticulatus).
If ticks of some species (Dermacentor reticulatus) are already present
when the
product is applied, all of the ticks may not be killed within the
first 48 hours.
4.3
CONTRAINDICATIONS
Do not use on puppies less than 2 months old and /or weighing less
than 20 kg. Do
not use on sick (e.g. systemic diseases, fever…) or convalescent
animals.
Do not use in rabbits, as adverse reactions and even death could
occur.
Page 1 of 6
Revised: May 2018
AN: 01756/2017
This product is specifically developed for dogs. Do not use in cats,
as this could lead
to overdosing.
Do not use on animals with known hypersensitivity to the active
substance or to any
of the excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Avoid frequent swimming or shampooing the animal because the
maintenance of
effectiveness of the product in these cases has not been tested.
The product does not prevent ticks from attaching to the animals. If
the animal has
been treated prior to exposure to the ticks, the ticks will be killed
in the first 24-48
hours after attachment. This will usually be prior to engorgement,
minimising but not
excluding the risk o
                                
                                Read the complete document